X4 Pharmaceuticals is a biopharmaceutical company developing and commercializing therapeutics for rare hematology diseases. Its primary asset is mavorixafor, an oral small-molecule selective antagonist of the CXCR4 chemokine receptor. The company has one commercially approved product, XOLREMDI (mavorixafor), which received FDA accelerated approval in the United States for the treatment of WHIM syndrome. Mavorixafor is currently undergoing a global Phase 3 clinical trial, the 4WARD trial, to evaluate its efficacy in patients with chronic neutropenia. The company serves patients in the U.S. and internationally, with Norgine Pharma UK Ltd. acting as its commercialization partner in Europe. X4 Pharmaceuticals focuses on providing oral alternatives to injectable therapies for conditions characterized by low neutrophil counts.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage x4pharma.com
Sector Healthcare IR page investors.x4pharma.com
Tags
rare diseases, hematology, chronic neutropenia, whim syndrome, cxcr4 antagonist, small molecule, immunodeficiency, oral therapy, mavorixafor, XOLREMDI, 4WARD trial, Norgine Pharma UK Ltd.
Press page —

Metrics

Valuation  
Market cap $ 260.674M
Market cap (USD) $ 260.674M
P/E 4.70
PEG —
P/BV 1.88
P/S 15.37
P/OCF -3.43
P/FCF -3.04
Dividend yield —
Turnover / mcap —
Returns  
ROE -76.0%
ROI -30.3%
ROIC -24.9%
Profit margin -225.6%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock —
Diluting (TTM) —
Debt/Equity 54.0%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 36
Quality score -30.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Revenue 35.113M 2.557M — 0 0 3M — 3.5M —
Net profit -79.199M -37.45M -101.167M -93.867M -88.696M -62.131M -52.807M -43.021M -33.877M
Free cash flow -85.618M -131.227M -96.572M -77.205M -71.52M -60.18M -48.229M -40.937M -27.913M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Share price 4 0.37 0.9 1.21 5.1 7 — — —
Price performance 12m 9.96 -0.59 -0.26 -0.76 -0.27 — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — — 0.00 — — — 0.00 1.07M 573,000
↳ YoY growth -46.4%
Borrowings, current (USD) — — 1.69M 0.00 0.00 795,000 1.32M 0.00 — —
Borrowings, non-current (USD) — — 8.31M 20M 33.2M 33.1M 32.3M 54.6M — —
Lease liabilities (USD) — — — 2.82M 5.27M 5.85M 4.8M 3.71M 2.66M 994,000
Cash and deposits (USD) 3.04M 76.8M 30.8M 126M 78.7M 81.8M 122M 99.2M 55.7M 217M
Intangible assets (USD) — — — — — — — 0.00 10M 9.25M
Right-of-use assets (USD) — — — 1.96M 7.96M 8.71M 7.23M 5.65M 4.07M 1.41M
Net debt (borrowings + leases - cash) (USD) — — 1.87M -103M -73.4M -42M -83.3M -40.9M — —
Cash flow detail
Operating cash flow (USD) -21.6M -27.9M -40.9M -48.1M -58.8M -70.9M -77.1M -96.5M -131M -85.6M
Purchases of property, plant and equipment (USD) 73,000 42,000 -34,000 -174,000 -1.36M -615,000 -103,000 -60,000 -326,000 0.00
Purchases of intangible assets (USD) — — — — — — 0.00 0.00 -7M —
Change in receivables (cash effect) (USD) — — — — — — 0.00 0.00 -1.07M 497,000
Change in inventories (cash effect) (USD) — — — — — — 0.00 0.00 -2.82M -1.66M
Change in payables (cash effect) (USD) 1.26M 182,000 -1.34M -2.75M 1.03M 1.17M 3.43M 1.23M -286,000 -2.98M
Share buybacks (cash effect) (USD) — — — 0.00 0.00 -2M 0.00 0.00 — —
Interest paid (cash effect) (USD) -291,000 -309,000 -540,000 -1.28M -2.1M -2.91M -3.01M -4.6M -7.77M -8.05M
Income taxes paid (cash effect) (USD) — — — — — — — — — -338,000
Share-based compensation (USD) 644,000 906,000 5.62M 2.05M 5.43M 6.18M 5.2M 8.69M 8.2M 4.3M
Operating cash flow before change in receivables (USD) — — — — — — -77.1M -96.5M -130M -86.1M
Free cash flow (OCF - PPE - intangibles) (USD) -21.7M -27.9M -40.9M -48.2M -60.2M -71.5M -77.2M -96.6M -138M -85.6M
Income detail
Research and development expense (USD) 17.8M 28.1M 31M 30.2M 41.9M 50.6M 61.1M 72M 81.6M 72.7M
↳ 5y CAGR +27.0% +23.2% +16.8% +18.4% +22.0% +11.6%
Total comprehensive income (USD) -22.9M -34.6M -42.9M -52.9M -62.1M -88.7M -93.9M -101M -37.5M —
Comprehensive income to owners (USD) -22.9M -34.6M -42.9M -52.9M -62.1M -88.7M -93.9M -101M -37.5M —
Reported Mar 11, 2019 Mar 11, 2019 Mar 12, 2020 Mar 17, 2022 Mar 17, 2022 Mar 17, 2022 Mar 26, 2025 Mar 26, 2025 Mar 26, 2025 Mar 17, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

X4 Pharmaceuticals, Inc. — Other Events Bull 0 Bear 0 Routine

On October 29, 2026, X4 Pharmaceuticals, Inc. (the “Company”) will be posting to its website an investor presentation to be used in the Company’s October 29, 2029 Investor Day event. A copy of the presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

To access the presentation, investors should visit the “Investors” section of the Company’s website at www.x4pharma.com.

October 29, 2026

PDF Version

  • Base Case U.S. Market Opportunity Estimated at 15,000 Patients, With Potential to Expand to Approximately 30,000 Patients -

  • On Track for Completion of 4WARD Phase 3 Target Enrollment in Q4 2026 -

  • Planned 4STEPS Phase 2b Trial Evaluating G-CSF Dose Reduction with Mavorixafor; Initiation Expected in Q1 2027 -

  • Topline Data from Both 4WARD and 4STEPS Expected in Q1 2028 -

BOSTON, Oct. 29, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today hosted a virtual Investor Day highlighting the U.S. market opportunity for mavorixafor, an investigational, once-daily oral CXCR4 antagonist, in primary chronic neutropenia (PCN). The event featured a clinical program update, new market research, and a fireside chat with key opinion leaders, Shreyans Gandhi, M.D., of King’s College Hospital NHS Foundation Trust, London, and Julia Warren, M.D., Ph.D., of Children’s Hospital of Philadelphia.

“PCN is a serious, chronic disease with no new therapy approved in more than 30 years, and today we outlined a clear path to potentially bring the first once-daily oral therapy to people living with this disease,” said Adam Craig, M.D., Ph.D., Executive Chair of X4 Pharmaceuticals. “Our 4WARD Phase 3 trial is designed to clearly measure the clinical benefit of mavorixafor, and we remain on track to fully enroll the study by year end. Our planned 4STEPS Phase 2b trial is designed to complement 4WARD by evaluating whether granulocyte colony-stimulating factor (G-CSF) dosage can be reduced or discontinued after initiating mavorixafor. Our most recent commercial research supports a U.S. market opportunity of approximately 15,000 patients, with the potential to grow to approximately 30,000. With data from both trials expected in Q1 2028, we look forward to a milestone-rich next 18 months.”

Anticipated milestones:

  • Complete target enrollment in 4WARD Phase 3 trial: Q4 2026

  • First participant enrolled in 4STEPS Phase 2b trial: Q1 2027

  • Topline data from both 4WARD and 4STEPS trials: Q1 2028

  • If 4WARD results are positive, potential U.S. Food and Drug Administration (FDA) approval of mavorixafor in PCN in late 2028 or early 2029

Market Opportunity Highlights

  • PCN is a heterogeneous disease that is often underdiagnosed and misdiagnosed, which X4 believes has resulted in a large, underserved patient population.

  • Claims data identified approximately 15,000 symptomatic U.S. patients aged 12 and older with an absolute neutrophil count (ANC) below 1,000 cells/µL and two or more infections in 2025. This base-case population is consistent with patients enrolled in the 4WARD Phase 3 trial.

  • Claims data has also identified a potential expansion opportunity, subject to FDA labeling, of 30,000 U.S. patients with an ANC below 1,000 cells/µL and one or more infections in 2025.

  • Current treatment options are limited to G-CSF injections and antibiotics, and X4 believes a significant unmet medical need remains despite these therapies.

  • There is currently no approved oral therapy for PCN, and patients may rely on off-label or burdensome treatments.

Clinical Program Update

  • Completion of target enrollment of 126 participants in 4WARD is expected in the fourth quarter of 2026. Blinded, pooled baseline characteristic data as of September 2026 show a median ANC of 483 cells/µL, with 68% of participants having three or more infections at baseline.

  • X4 introduced 4STEPS, a planned Phase 2b trial designed to evaluate whether G-CSF dosage can be safely reduced after starting mavorixafor while maintaining stable neutrophil counts, with the first participant expected to be enrolled in the first quarter of 2027.

  • Topline data from both 4WARD and 4STEPS trials are expected in the first quarter of 2028.

  • If positive, the 4WARD results could support a regulatory submission for mavorixafor in PCN, with potential FDA approval in late 2028 or early 2029.

Webcast Replay

A replay of the Investor Day webcast and the accompanying slide presentation are available in the Events & Presentations section of the X4 Investor Relations website here.

About Mavorixafor

Mavorixafor is a small molecule delivered in a capsule for oral dosing as a selective antagonist of the chemokine receptor, CXCR4. Down-regulation of the CXCR4 receptor by mavorixafor has been shown to mobilize functional neutrophils from the bone marrow into the peripheral bloodstream across multiple disease states. The level of circulating neutrophils is typically determined by the absolute neutrophil count (ANC) obtained from a blood draw. Mavorixafor is approved in the U.S. and the European Union as XOLREMDI® for the treatment of patients 12 years and older with WHIM syndrome. Mavorixafor is also being evaluated for the treatment of primary chronic neutropenia in a Phase 3 clinical trial. The FDA has granted Fast Track designation to mavorixafor for the treatment of chronic neutropenia.

About Primary Chronic Neutropenia

Primary chronic neutropenia (PCN) is a rare blood condition characterized by abnormally low levels of circulating neutrophils in the blood lasting more than three months, persistently or intermittently. As a result, people with PCN are at an increased risk of serious and life-threatening infections and reduced quality of life. Neutrophils are retained in the bone marrow by the CXCR4/CXCL12 axis, creating a reserve of cells. PCN is a heterogeneous disease that includes idiopathic, congenital, cyclic, and autoimmune forms, and is often underdiagnosed and misdiagnosed.

About X4 Pharmaceuticals

X4 Pharmaceuticals is a company focused on improving the lives of people with rare hematology diseases by developing and commercializing innovative therapies in areas with significant unmet medical needs. Leveraging expertise in diseases of the immune system and CXCR4 biology, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is approved in the U.S. and EU as XOLREMDI® for patients with WHIM syndrome. The Company is currently conducting a global, pivotal Phase 3 clinical trial (4WARD) evaluating mavorixafor in chronic neutropenic disorders. The U.S. FDA has granted Fast Track designation to mavorixafor for the treatment of chronic neutropenia. X4 is headquartered in Boston, Massachusetts. For more information, please visit www.x4pharma.com.

X4 Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by the words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target,” or other similar terms or expressions that concern X4’s expectations, strategy, plans, or intentions. Forward-looking statements include, without limitation, implied or express statements regarding the design of, and timing of completion of target enrollment in, the 4WARD trial; the design, initiation, enrollment and timing of the planned 4STEPS trial; the timing of topline data from 4WARD and 4STEPS; the potential regulatory approval of mavorixafor in chronic neutropenia and the timing thereof; the size of the potential market opportunity and addressable patient population for mavorixafor in PCN, including potential expansion opportunities; the potential therapeutic benefits and commercial potential of mavorixafor, including the potential for mavorixafor to be the first once-daily oral therapy for PCN and to permit reduction or discontinuation of G-CSF; X4’s anticipated milestones; and other future plans for the Company. Any forward-looking statements in this press release are based on management’s current expectations and beliefs. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond X4’s control, which could cause actual results to differ materially from those contemplated in these forward-looking statements, including risks related to the initiation, enrollment, conduct, timing and results of clinical trials; feedback from regulatory authorities; the limitations of market research and claims data analyses; X4’s ability to obtain sufficient capital; and other risks and uncertainties, including those described in the section entitled “Risk Factors” in X4’s most recent Annual Report on Form 10-K, as well as in other filings X4 makes with the Securities and Exchange Commission from time to time, including its Quarterly Reports on Form 10-Q. X4 undertakes no obligation to update the information contained in this press release to reflect new events or circumstances, except as required by law.

X4 Investor Contact: Remy Bernarda Jenny Kobin IR Advisory Solutions [email protected]

Source: X4 Pharmaceuticals, Inc.

© 2026 X4 Pharmaceuticals, Inc. All rights reserved.

Live - Footer

Terms of Use | Privacy | Compliance and Ethics

October 9, 2026

PDF Version

BOSTON, Oct. 09, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that the Company will host a virtual Investor Day on Thursday, October 29, 2026, from 10:00 a.m. to 12:00 p.m. ET.

The Investor Day will feature discussions with X4 Pharmaceuticals management and key opinion leaders on mavorixafor as a potential treatment for chronic neutropenia. Management will review the current status of the Phase 3 4WARD clinical trial and will outline a planned Phase 2 clinical trial of mavorixafor in combination with granulocyte colony-stimulating factor (G-CSF), designed to assess patients' ability to titrate down their G-CSF dose while maintaining normal neutrophil counts.

The Company will also present the potential commercial opportunity for mavorixafor in chronic neutropenia. Following management’s presentation, Dr. Adam Craig, X4 Pharmaceuticals’ Executive Chairman, will host a fireside chat with leading hematology experts, Dr. Shreyans Gandhi and Dr. Julia Warren, followed by a Q&A session.

Webcast Registration:

Registration for the event is available on the Events and Presentations page of the X4 Pharmaceuticals website. An archived replay will also be available on the X4 Pharmaceuticals website following the event.

X4 Pharmaceuticals Investor Day Guest Speakers

Shreyans Gandhi, MBBS, MD, DNB (Internal Medicine), MRCP, FRCPath, M.Phil King’s College Hospital NHS Foundation Trust (London)

Dr. Gandhi is a Consultant Haematologist at King’s College Hospital in London, working in the field of myeloid disorders, with a primary interest in bone marrow failure (BMF)/cytopenic disorders and paroxysmal nocturnal hemoglobinuria (PNH), including cellular therapies and stem cell transplantation. He is actively involved in academia, being a college tutor for medical students, trainer/supervisor for junior haematology trainees and examiner at the Royal College of Pathologists, and he has authored more than 100 articles in peer-reviewed journals, and chapters for national textbooks. He is an Associate Editor on the board of Frontiers in Oncology and has reviewer and editorial responsibilities in leading medical and haematological journals. He has served as Chair of the South London Cancer Alliance in Haemato-Oncology, including updating of treatment guidelines.

Dr. Gandhi completed his medical degree (MBBS) and thereafter a residency programme in Internal Medicine (MD and Diplomate of National Board) at King Edward Memorial (KEM) Hospital, University of Mumbai with a first-class MD. He is a member of the Royal College of Physicians and gained his fellowship in haematology and specialist training in bone marrow failure disorders at King’s College Hospital in London. He is actively involved in the academic and research activities at the BMF unit at King’s College Hospital.

Dr. Gandhi pursues research on telomere genetic disorders and its multi-system manifestation in BMF. His bench work on RTEL1 was published in Blood Advances. He has been an investigator on numerous Phase 1-3 clinical trials, including cellular therapies and on novel anti-complement drugs. His current academic and research work involve the development and application of ex-vivo expanded T regulatory cells in aplastic anaemia and other auto-immune disorders, the genetic characterization and algorithms in the diagnosis and manifestation of BMF disorders, and the development of a novel assay to assess telomerase activity. Dr. Gandhi has lectured extensively on BMF and PNH and enjoys being a patient advocate at various patient support group societies (aplastic anaemia/PNH and myelodysplastic syndromes and has also represented the rare disease groups (BMF) at the Health Select Committee of the United Kingdom Parliament.

Julia Warren, MD, PhD Children's Hospital of Philadelphia and University of Pennsylvania

Dr. Warren is a pediatric hematologist and physician-scientist at the University of Pennsylvania and Children's Hospital of Philadelphia (CHOP), and an Assistant Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania (Penn Medicine). Her laboratory program at CHOP/Penn Medicine is focused on understanding mitochondrial function in early granulocyte fate decisions, as well as pre-malignant clonal evolution in congenital neutropenia. Her long-term goals are to understand determinants of normal granulopoiesis that will support the production of off-the-shelf granulocyte transfusion products, and to better identify and treat pre-malignant myeloid clones in bone marrow failure syndromes. Dr. Warren’s research has been supported by the National Heart, Lung, and Blood Institute (NHLBI) and the American Society of Hematology (ASH), among others. Her research interests continue to be informed by her patients, whom she sees through CHOP’s Comprehensive Bone Marrow Failure Center and Cancer Predisposition Clinic programs, with a specialized interest in patients with chronic neutropenia disorders.

Dr. Warren completed her MD and PhD (Immunology) training at Washington University in St. Louis, followed by pediatric residency and hematology/oncology fellowship training as a member of the Oliver Langenberg Physician-Scientist Training Program at Washington University in St. Louis. Her fellowship research focused on normal and malignant myeloid biology and included the identification of novel germline genetic variants impacting mitochondrial function as a cause of congenital neutropenia. Her work also provided evidence for mitochondrial dysfunction in impaired granulocyte precursor survival/differentiation.

About X4 Pharmaceuticals

X4 Pharmaceuticals is a company focused on improving the lives of people with rare hematology diseases by developing and commercializing innovative therapies in areas with significant unmet needs. Leveraging expertise in diseases of the immune system and CXCR4 biology, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is approved in the U.S. and EU as XOLREMDI® for patients with WHIM syndrome. The Company is currently conducting a global, pivotal Phase 3 clinical trial (4WARD) evaluating mavorixafor in chronic neutropenic disorders. The U.S. FDA has granted Fast Track designation to mavorixafor for the treatment of chronic neutropenia. X4 is headquartered in Boston, Massachusetts. For more information, please visit www.x4pharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by the words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target,” or other similar terms or expressions that concern X4’s expectations, strategy, plans, or intentions. Forward-looking statements include, without limitation, implied or express statements regarding the status of the Phase 3 4WARD clinical trial; the design, objectives and initiation of a planned Phase 2 clinical trial of mavorixafor in combination with G-CSF; the potential of mavorixafor as a treatment for chronic neutropenia; and the potential commercial opportunity for mavorixafor in chronic neutropenia. Any forward-looking statements in this press release are based on management’s current expectations and beliefs. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond X4’s control, which could cause actual results to differ materially from those contemplated in these forward-looking statements, including the risks related to the initiation, enrollment, conduct, timing and results of clinical trials; feedback from regulatory authorities; the limitations of market research; X4’s ability to obtain sufficient capital; and other risks and uncertainties, including those described in the section entitled “Risk Factors” in X4’s most recent Annual Report on Form 10-K, as well as in other filings X4 makes with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q, from time to time. X4 undertakes no obligation to update the information contained in this press release to reflect new events or circumstances, except as required by law.

X4 Investor Contact: Remy Bernarda Jenny Kobin IR Advisory Solutions [email protected]

Source: X4 Pharmaceuticals, Inc.

© 2026 X4 Pharmaceuticals, Inc. All rights reserved.

Live - Footer

Terms of Use | Privacy | Compliance and Ethics

Prompts

X4 Pharmaceuticals, Inc. (ticker XFOR), listed in United States.

Company History

Date Change Detail
Feb 8, 2019 Renamed ARSANIS, INC. → X4 PHARMACEUTICALS, INC

ETFs Holding X4 Pharmaceuticals, Inc.

ETF Weight in ETF Shares Market value As of
AVSC 0.01% 108,750 $ 307.763K Nov 16, 2026
MSSM 0.00% 7,074 $ 28.579K Aug 31, 2026